Vanda Pharmaceuticals (VNDA) announced that the U.S. FDA informed Vanda that the New Drug Application for Bysanti has been filed, and that at this time no potential review issues have been identified. The FDA has set February 21, 2026 as the target date for decision on this application.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals (VNDA) Q1 Earnings Cheat Sheet
- Vanda says FDA ‘unlawfully’ delaying hearing
- Vanda Pharmaceuticals: Strategic Advancements and Financial Strength Underpin Buy Rating
- Vanda Pharmaceuticals submits NDA to FDA for Bysanti
- Positive Outlook for Vanda Pharmaceuticals: FDA Acceptance and Strong Financial Position Bolster Buy Rating